{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:05:27Z","timestamp":1793480727276,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.parkreldis.2025.107939","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:17:28Z","timestamp":1750792648000},"page":"107939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Tau positron emission tomography in the Parkinson and Richardson subtypes of progressive supranuclear palsy"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-6817","authenticated-orcid":false,"given":"Piotr","family":"Alster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8685-475X","authenticated-orcid":false,"given":"Natalia","family":"Madetko-Alster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2025.107939_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107109","article-title":"Relationships between regional burden of tau pathology and age at death and disease duration in PSP","volume":"127","author":"Badihian","year":"2024","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107939_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107939_bib5","first-page":"301","article-title":"Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system","volume":"11","author":"van Eimeren","year":"2019","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.parkreldis.2025.107939_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.571800","article-title":"Clinical features of patients with progressive supranuclear palsy in an US insurance claims database","volume":"12","author":"Viscidi","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107939_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fneur.2020.00180","article-title":"Progressive supranuclear palsy-parkinsonism predominant (PSP-P)-A clinical challenge at the boundaries of PSP and Parkinson's disease (PD)","volume":"11","author":"Alster","year":"2020","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.parkreldis.2025.107939_bib8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11910-018-0898-3","article-title":"The role of tau imaging in parkinsonian disorders","volume":"18","author":"Hammes","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00401-024-02834-7","article-title":"Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies","volume":"148","author":"Slemann","year":"2024","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib10","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41598-024-53355-y","article-title":"The significance of glial cell line-derived neurotrophic factor analysis in progressive supranuclear palsy","volume":"14","author":"Alster","year":"2024","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.parkreldis.2025.107939_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015135","article-title":"Clinical phenotypes of progressive supranuclear palsy-the differences in interleukin patterns","volume":"24","author":"Madetko-Alster","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107939_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3552","article-title":"The potential significance of hepcidin evaluation in progressive supranuclear palsy","volume":"14","author":"Alster","year":"2024","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2025.107939_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2022.11.018","article-title":"Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy","volume":"106","author":"Oliveira Hauer","year":"2023","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107939_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2025.107939_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.arr.2015.12.010","article-title":"Advances in the development of tau PET radiotracers and their clinical applications","volume":"30","author":"Okamura","year":"2016","journal-title":"Ageing Res. Rev."},{"issue":"8","key":"10.1016\/j.parkreldis.2025.107939_bib16","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1021\/acschemneuro.9b00326","article-title":"Identification of AV-1451 as a weak, nonselective inhibitor of monoamine oxidase","volume":"10","author":"Drake","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mds.26813","article-title":"Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy","volume":"32","author":"Smith","year":"2017","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.107939_bib18","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","article-title":"Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies","volume":"46","author":"Kroth","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107939_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","article-title":"The development and validation of tau PET tracers: current status and future directions","volume":"6","author":"Okamura","year":"2018","journal-title":"Clin. Transl. Imaging."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.107939_bib20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ana.24517","article-title":"Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue","volume":"78","author":"Marqui\u00e9","year":"2015","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mds.26727","article-title":"Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy","volume":"32","author":"Hammes","year":"2017","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.107939_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2967\/jnumed.121.262985","article-title":"In vivo 18F-Flortaucipir PET Does Not AdcuranelyaSupport ths Staging ofsProgressivp Supranuclesr Palsy","volume":"63","author":"Malpetti","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.parkreldis.2025.107939_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102152","article-title":"Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants","volume":"25","author":"Whitwell","year":"2020","journal-title":"Neuroimage Clin."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00401-024-02712-2","article-title":"Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in alzheimer's disease and related dementias","volume":"147","author":"Jaisa-Aad","year":"2024","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.27546","article-title":"MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy","volume":"34","author":"Whitwell","year":"2019","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2025.107939_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","article-title":"Neuroinflammation predicts disease progression in progressive supranuclear palsy","volume":"92","author":"Malpetti","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107939_bib27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2967\/jnumed.121.262685","article-title":"Relationship between 18F-Flortaucipir Uptake anduHistologichLesion Typls in 4tRepeat Tauopathiet","volume":"63","author":"Josephs","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.parkreldis.2025.107939_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/RLU.0000000000002949","article-title":"Tau imaging in the 4-Repeat-Tauopathies progressive supranuclear palsy and corticobasal syndrome: a 11C-Pyridinyl-Butadienyl-Benzothiazole 3 PET pilot study","volume":"45","author":"Schr\u00f6ter","year":"2020","journal-title":"Clin. Nucl. Med."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.107939_bib29","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.parkreldis.2015.08.011","article-title":"Imaging biomarkers in tauopathies","volume":"22","author":"Dani","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.107939_bib30","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1093\/brain\/awz238","article-title":"PET-detectable tau pathology correlates with long-te neuropsychiatric outcomes in patients with traumatic brain injury","volume":"142","author":"Takahata","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40478-018-0556-7","article-title":"Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy","volume":"6","author":"Ishiki","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.13164","article-title":"Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy","volume":"24","author":"Ishiki","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-017-0253-y","article-title":"Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain","volume":"9","author":"Ng","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.parkreldis.2025.107939_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.761010","article-title":"18F-THK5351 positron emission tomography imaging in neurodegenerative tauopathies","volume":"13","author":"Ezura","year":"2021","journal-title":"Front. Aging Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib35","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1038\/s41598-021-83535-z","article-title":"18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty","volume":"11","author":"Hsu","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2025.107939_bib36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3389\/fnagi.2017.00440","article-title":"[18F]-THK5351 PET Correlatescwith Topology atd Symptom Severity is Progressivp Supranuclesr Palsy","volume":"9","author":"Brendel","year":"2018","journal-title":"Front. Aging Neurosci."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107939_bib37","first-page":"1754","article-title":"18F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy","volume":"63","author":"Messerschmidt","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.parkreldis.2025.107939_bib38","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1007\/s00259-021-05391-3","article-title":"Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy","volume":"48","author":"Song","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107939_bib39","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3233\/JPD-240210","article-title":"Progressive supranuclear palsy: subcortical tau depositions are associated with cortical perfusion in frontal and limbic regions","volume":"14","author":"Theis","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2025.107939_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"12","key":"10.1016\/j.parkreldis.2025.107939_bib41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/acn3.339","article-title":"Impact of tau and amyloid burden on glucose metabolism in alzheimer's disease","volume":"3","author":"Bischof","year":"2016","journal-title":"Ann Clin. Transl. Neurol."},{"key":"10.1016\/j.parkreldis.2025.107939_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103402","article-title":"Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal","volume":"38","author":"Sch\u00f6necker","year":"2023","journal-title":"Neuroimage Clin."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107939_bib43","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1177\/0271678X211018904","article-title":"Binding characteristics of [18F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET","volume":"41","author":"Song","year":"2021","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"10","key":"10.1016\/j.parkreldis.2025.107939_bib44","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1002\/alz.14185","article-title":"Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of alzheimer's disease and 4R-tauopathies","volume":"20","author":"Dilcher","year":"2024","journal-title":"Alzheimer's Dement."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107939_bib45","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1007\/s00259-024-06741-7","article-title":"Assessment of [18F]PI-2620 Tau-PET Quantificaqion via Non-Invasinon-itomatizea Image Deriied Indut Funciion","volume":"51","author":"Meindl","year":"2024","journal-title":"fur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib46","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41467-022-28896-3","article-title":"Tau deposition patterns are associated with functional connectivity in primary tauopathies","volume":"13","author":"Franzmeier","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.107939_bib47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-022-06104-0","article-title":"18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy","volume":"50","author":"Liu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.107939_bib48","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/mds.29173","article-title":"A machine learning-based approach to discrimination of tauopathies using [18 F]PM-PBB3 PET images","volume":"37","author":"Endo","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2025.107939_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117440","article-title":"A case of progressive supranuclear palsy with predominant cerebellar ataxia diagnosed by [18F]PM-PBB3 tau PET","volume":"425","author":"Ishizuchi","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JAD-200287","article-title":"Tau PET imaging with [18F]PM-PBB3 in frontotemporal dementia with MAPT mutation","volume":"76","author":"Su","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.parkreldis.2025.107939_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000121388","article-title":"Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy","volume":"5","author":"Jellinger","year":"2008","journal-title":"Neurodegener. Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2025.107939_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40478-024-01844-6","article-title":"Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription","volume":"12","author":"Jackson","year":"2024","journal-title":"Acta Neuropathol. Commun."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025006807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T22:42:59Z","timestamp":1752878579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025006807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"alternative-id":["S1353802025006807"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107939","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tau positron emission tomography in the Parkinson and Richardson subtypes of progressive supranuclear palsy","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107939"}}